Physician profile
Roman I Czubatyj
NPI 1972797892
$763,549.63
in general payments reported to CMS, 2019-2025
34 companies · $135K in 2025
The $135K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $47K · 2021: $60K · 2022: $111K · 2023: $156K · 2024: $184K · 2025: $135K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $319K · Honoraria: $95K · Travel and Lodging: $30K · Food and Beverage: $19K · Consulting Fee: $12K · Education: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $318,607.50 |
| Honoraria | $95,265.00 |
| Travel and Lodging | $30,169.38 |
| Food and Beverage | $18,992.33 |
| Consulting Fee | $11,994.00 |
| Education | $539.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $287,849.46 | 2019-2023 | Krystexxa, Tepezza |
| Amgen INC. | $227,980.79 | 2019-2025 | Krystexxa, Uplizna, Tavneos |
| Abbvie INC. | $138,708.54 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $85,321.02 | 2019-2025 | Simponi Aria, Tremfya, Remicade |
| Janssen Scientific Affairs, LLC | $17,780.86 | 2022-2023 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $962.92 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $924.93 | 2019-2025 | |
| Genzyme Corporation | $859.26 | 2023-2025 | |
| Lilly USA, LLC | $565.06 | 2019-2025 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $533.20 | 2019-2025 | Orencia |
| Pfizer INC. | $478.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $465.28 | 2019-2025 | Benlysta |
| Sandoz INC. | $176.47 | 2023-2025 | Hyrimoz, Jubbonti |
| Astrazeneca Pharmaceuticals Lp | $129.73 | 2021-2025 | Saphnelo |
| Intrafusion Gp, LLC | $110.35 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $90.90 | 2023-2025 | Hadlima, Renflexis |
| Genentech USA, INC. | $89.76 | 2019-2025 | Gazyva, Actemra |
| Fresenius Kabi USA, LLC | $79.04 | 2024-2025 | Idacio |
| Sanofi-Aventis U.S. LLC | $64.99 | 2023 | |
| Pacira Therapeutics, INC. | $49.55 | 2019 | |
| Cardinal Health INC | $42.85 | 2024 | |
| Aurinia Pharma U.S., INC. | $41.86 | 2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.85 | 2024 | Cyltezo |
| Hikma Pharmaceuticals USA | $28.71 | 2019 | |
| Sobi, INC | $28.42 | 2021 | |
| Ani Pharmaceuticals, INC. | $26.25 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $20.07 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.75 | 2022 | |
| Antares Pharma, INC. | $16.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.85 | 2019 | |
| Merck Sharp & Dohme LLC | $15.53 | 2020 | |
| Arcutis Biotherapeutics, INC. | $15.20 | 2023 | |
| Ferring Pharmaceuticals INC. | $14.59 | 2019 | |
| Bioventus LLC | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Czubatyj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.